Real-world outcomes of cytokine-modulating treatment strategies in severe COVID-19 pneumonia: A multicenter observational cohort
During the coronavirus disease 2019 (COVID-19) pandemic, different immunomodulatory strategies were adopted in routine practice. However, treatment selection often depends on illness severity and resource availability, and interpreting real-world outcomes is challenging. We aimed to describe clinical outcomes according to cytokine-modulating treatment strategies in severe COVID-19 pneumonia. We conducted a multicenter ambispective observational cohort study including adults with severe COVID-19 pneumonia treated with either tocilizumab or hemoperfusion between January 2020 and December 2021. Treatment allocation was determined by treating physicians under real-world conditions. The primary outcome was 30-day all-cause mortality. Multivariable Cox regression was used to explore factors associated with mortality. Ninety-two patients were included (tocilizumab n = 67; hemoperfusion n = 25). Patients receiving hemoperfusion had substantially greater baseline illness severity. C-reactive protein declined after treatment in both groups. Crude 30-day mortality was 22.4% in the tocilizumab group and 60.0% in the hemoperfusion group. Treatment modality was not statistically associated with mortality after adjustment (adjusted hazard ratio, 0.70; 95% confidence interval, 0.28-1.72), whereas a Sequential Organ Failure Assessment (SOFA) score ≥3 and higher baseline interleukin-6 (IL-6) were associated with mortality. Among patients with lower illness severity (SOFA <3), tocilizumab showed a nonsignificant trend toward improved survival. In this real-world cohort, baseline disease severity rather than treatment modality was the dominant determinant of outcome. Tocilizumab was more commonly used at earlier disease stages, whereas hemoperfusion was preferred in patients with clinical deterioration. These findings highlight the importance of patient selection when interpreting treatment outcomes in observational studies of severe COVID-19.
Authors
- Kulapong Jayanama (ORCID: https://orcid.org/0000-0002-4237-2756)
- Ittikorn Spanuchart (ORCID: https://orcid.org/0000-0002-9159-0071)
- Lerkiat Wicharit (ORCID: https://orcid.org/0009-0000-3053-7798)
- Supawadee Suppadungsuk (ORCID: https://orcid.org/0000-0003-1597-2411)
- Adisorn Pathumarak
- Kanin Thammavaranucupt (ORCID: https://orcid.org/0000-0002-9873-3848)
- Suwit Wankaew
Institutions
- Mahidol University (TH)
- University of Michigan (US)
- Michigan Medicine (US)
- Ramathibodi Hospital (TH)
- Ramathibodi Chakri Naruebodindra Hospital (TH)
- Boromarajonani College of Nursing, Nakhon Ratchasima (TH)
Publication Details
- Journal
- Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1097/md.0000000000051604
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00